Enlicitide Decanoate for hypercholesterolemia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 6 registered trials.

Why this status

  1. 19 Jul 2023: Trial registered, NCT05952856
  2. 19 Jul 2023: Trial registered, NCT05952869
  3. 8 Aug 2023: Trial started, NCT05952869
  4. 10 Aug 2023: Trial started, NCT05952856
  5. 24 Aug 2023: Trial registered, NCT06008756
  6. 9 Oct 2023: Trial started, NCT06008756
  7. 9 Jul 2024: Trial registered, NCT06492291
  8. 5 Aug 2024: Trial started, NCT06492291
  9. 16 Sep 2026: Trial registered, NCT07821944
  10. 15 Oct 2026: Trial started, NCT07821944

The trials

NCT05261126: A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

State
Completed
Phase
Phase 2
People
381 taking part
Started
10 Mar 2022
Primary completion
28 Nov 2022
Arms
Enclitide Chloride 6 mg, Enclitide Chloride 12 mg, Enclitide Chloride 18 mg, Enclitide Chloride 30 mg
Results
Posted on the registry
  1. 2 Mar 2022: Trial registered
  2. 10 Mar 2022: Trial started
  3. 28 Nov 2022: Trial completed
  4. 6 Dec 2023: Trial results posted

NCT05952856: A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

State
Completed
Phase
Phase 3
People
2,912 taking part
Started
10 Aug 2023
Primary completion
28 Jul 2025
Arms
Enlicitide Decanoate
Results
Posted on the registry
  1. 19 Jul 2023: Trial registered
  2. 10 Aug 2023: Trial started
  3. 28 Jul 2025: Trial completed
  4. 6 Aug 2026: Trial results posted

NCT05952869: A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

State
Completed
Phase
Phase 3
People
303 taking part
Started
8 Aug 2023
Primary completion
7 Apr 2025
Arms
Enlicitide Decanoate
Results
Posted on the registry
  1. 19 Jul 2023: Trial registered
  2. 8 Aug 2023: Trial started
  3. 7 Apr 2025: Trial completed
  4. 24 Feb 2026: Trial results posted

NCT06008756: Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

State
Under way
Phase
Phase 3
People
14,550 planned
Started
9 Oct 2023
Primary completion
29 Nov 2029
Arms
Blinded Portion: Enlicitide Decanoate, Open-Label Extension: Enlicitide Decanoate
Results
None posted
  1. 24 Aug 2023: Trial registered
  2. 9 Oct 2023: Trial started

NCT06492291: Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

State
Under way
Phase
Phase 3
People
3,000 planned
Started
5 Aug 2024
Primary completion
13 Oct 2028
Arms
Enlicitide Decanoate
Results
None posted
  1. 9 Jul 2024: Trial registered
  2. 5 Aug 2024: Trial started

NCT07821944: A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)

State
Under way
Phase
Phase 3
People
150 planned
Started
15 Oct 2026
Primary completion
26 Nov 2027
Arms
Enlicitide Decanoate
Results
None posted
  1. 16 Sep 2026: Trial registered
  2. 15 Oct 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Enclitide Chloride, Lipfendra.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.